Arch Oncology

Arch Oncology

 

Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Their functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.